Cholesterol screening and treatment for younger adults, new guidelines suggest

New joint AHA/ACC cholesterol guidelines advise screening and considering treatment starting in patients in their 30s and recommend using the PREVENT calculator for 10- and 30-year atherosclerotic cardiovascular disease risk. Key numeric thresholds: statins recommended for LDL ≥160 mg/dL; LDL targets of <100 mg/dL for most, <70 mg/dL for high risk, and <55 mg/dL for established disease; Lp(a) testing once in adulthood with >250 nmol/L ≈ 2x risk and >430 nmol/L ≈ 4x risk. The guidance also adds apoB testing after LDL goal attainment and suggests coronary calcium screening for men ≥40 and women ≥45 with borderline/intermediate 10-year risk; ~25% of U.S. adults have high LDL and Lp(a) may affect ~64 million people in the U.S.

Analysis

Shifting prevention earlier creates a durable, front-loaded demand shock for diagnostic services and imaging that will play out over years, not weeks. Expect laboratories and outpatient imaging centers to see a multi-year tailwind as a larger cohort enters longitudinal monitoring — if primary care workflows and payers cooperate, addressable testing volume could rise high-single-digits to low-double-digits annually for the next 3–5 years.

The immediate winners are diagnostic testing (apoB, Lp(a)) and CT-based coronary calcium scanning: low per-test revenue but high frequency and stickiness. Equipment suppliers with install capacity (GE HealthCare, Philips, Siemens/ADR) gain both hardware and recurring software/analytics revenue; independent imaging operators (RadNet) can monetize increased scan throughput given typical CT ordering-to-install lead times of 6–12 months.

Pharma implications are asymmetric. Increased statin use favors cheap generics and broad retail channels, which caps near-term incremental branded pharma revenue; conversely, the formalization of Lp(a) testing increases optionality value for companies running Lp(a)-lowering programs (binary, multi-year upside). Payer economics — willingness to reimburse new tests and CAC scans for borderline/intermediate-risk adults — is the gating factor and the likeliest source of reversals within 12–24 months.

The consensus underestimates operational friction in primary care and overestimates immediate monetization of Lp(a). Testing adoption likely precedes therapeutic uptake by years, creating a predictable two-phase trade: durable diagnostic revenue first, therapy upside later if clinical trials succeed. That sequencing argues for being long infrastructure and diagnostics now and selectively long small-cap therapeutics via option structures to capture binary trial upside with defined capital at risk.

Key Decisions for Investors

• Long Quest Diagnostics (DGX) / Laboratory Corp (LH) — add 3–12% weight depending on cost basis; time horizon 6–18 months. Rationale: scalable incremental testing volumes (apoB, Lp(a)) and reflex testing. Risk: payer pushback or limited uptake could produce -10–20% drawdown; expected upside 15–30% if guideline adoption accelerates.
• Long GE HealthCare (GEHC) or Philips (PHG) — buy 6–12 month call spreads to limit capital. Rationale: CT scanner and analytics demand to support increased CAC scanning; lead times create revenue visibility. Risk/reward: limited downside via spreads, potential 20–40% upside in hardware/service revenue over 12 months if adoption grows.
• Speculative long Akcea (AKCA) or Ionis (IONS) — buy 12–36 month OTM call options (small allocation <1–2% portfolio). Rationale: Lp(a) testing increases market value of successful Lp(a)-lowering drugs; binary trial upside materially rerates clinical-stage names. Risk: high probability of failure or long timelines; treat as option on a multi-year therapy payoff.
• Long RadNet (RDNT) — accumulate a tactical position sized 1–3% over next 3 months. Rationale: outpatient imaging centers can capture margin expansion from incremental CAC scans and referrals. Risk: capital expenditure cycles, reimbursement delays; set stop at -15% and take-profits at +30% within 9–12 months.